• Capricorn Partners led Endo Tools Therapeutics’ oversubscribed Series C round, raising EUR 20 million to support commercialization.
• Endo Tools develops endoscopic suturing devices, anchored by the endomina platform for minimally invasive gastrointestinal procedures.
• Funding targets expansion in the U.S., Europe, the Middle East; includes rollout of the FDA-cleared endomina EZFuse system.
• Proceeds also earmarked to build clinical evidence for a U.S. weight-loss marketing indication for the platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricorn Partners NV published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.